Table 1.

Susceptibility in RPMI 1640 brotha

IsolateNPutative statusbMIC (μg/ml)c
48 h72 h
RangeGeo MModeRangeGeo MMode
CN 131S0.0625–0.50.260.250.25–10.470.5
CN 232S0.0625–0.50.240.250.125–20.410.25
CN 329S0.0625–0.50.270.250.125–10.360.5
CN 430S0.125–0.250.180.250.125–20.40.25
CN 530S0.125–0.50.220.250.125–10.370.5
CN 634S0.125–10.240.250.125–80.450.5
CN 731S0.125–0.50.290.250.125–80.540.5
CN 937S0.0625–0.50.150.1250.125–20.520.5
CN 1220S0.125–0.250.240.250.25–0.50.310.25
CN 844R0.5–20.910.5–41.311
CN 1020R1.0–2.01.2712.0–4.02.072
CN 1120R0.5–21.11222
Clinical72S0.125–0.50.360.50.125–10.460.5
  • a Eighty-four C. neoformansisolates were tested by the M27-A broth microdilution methodology in RPMI 1640 medium. Isolates CN 1 to CN 12 were tested the indicated number of times (N), while the 72 clinical isolates were tested once each. MICs were determined after 48 and 72 h of incubation.

  • b S, susceptible; R, resistant.

  • c Range, range of MICs; Geo M, geometric mean MIC; Mode, modal MIC.